Moderna doubles on a Phase 3 win whose effect size has not been published yet

Moderna and Merck said on Wednesday that intismeran autogene, an mRNA vaccine built from each patient's own tumour mutations, met both primary endpoints in the Phase 3 INTerpath-001 trial in patients whose melanoma had been surgically removed ^[1][2]. Moderna's stock rose about 131% to near $148, a record one-day move, repricing a company that had been leaning on a collapsed COVID franchise on the strength of a result whose actual effect size has not been released ^[3][16][7].

The trial enrolled 1,137 patients with high-risk stage IIB to IV melanoma, all resected before enrolment ^[10]. One arm received Keytruda plus the personalised vaccine up to nine times over roughly a year, the other Keytruda alone, which is the current standard of care in the adjuvant setting ^[11][14]. The combination beat it on recurrence-free and distant-metastasis-free survival at an interim analysis, with no new safety concerns identified ^[2][12][11]. The companies characterised the improvement only as "statistically significant and clinically meaningful" and said full data will go to a medical conference and to regulators ^[7]. Overall survival and other secondary endpoints have not been reported ^[13].

So investors are pricing the Phase 2 numbers Merck cited in its own release: a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death against Keytruda alone ^[8], from five-year follow-up published in January ^[9]. Danish Nagda, an otolaryngologist and chief executive of Rezilient Health, told Fortune that five-year recurrence-free survival in stage 3 and 4 melanoma currently runs around 20% to 35% and that the combination "potentially doubles it" ^[21]. That is one clinician's read, not trial data.

The asymmetry between the two partners is the part worth sitting with. Merck is valued at roughly $371bn against Moderna's roughly $62bn ^[19], about 17% of its partner ^[20]. Merck's shares rose about 10% in early trading ^[5], which on that base is roughly $34bn of market value ^[29] - approximately the entire gain Moderna booked on the day, since a 131% rise implies a pre-announcement value near $27bn ^[4][28]. For Merck this is an adjuvant extension of an existing franchise. For Moderna it is the first commercial argument for the platform that is not COVID.

Part of the move is mechanical. Short interest sat at 13.5% of free float and shorts took about $4.8bn in mark-to-market losses ^[17]. ORTEX co-founder Peter Hillerberg said each shorted share was "now down almost $100, that is exactly the kind of pressure that can trigger a squeeze" ^[18]. Early quotes also diverged: SCMP reported Moderna up more than 90% to about $120 ^[5], while a Reuters-sourced premarket quote carried by Seoul Economic Daily put the stock at $37.15, up 59% ^[6], a level that does not reconcile with the day's other prints.

The operational question the price is not yet answering is manufacture. Each dose requires sequencing an individual tumour and mapping its mutations, and the therapy is dosed up to nine times per patient ^[15][11]. That is a per-patient production line, not vials. The addressable population is real - the National Cancer Institute counted more than 1.5 million melanoma patients in the United States in 2023 ^[26] - but Merck Research Laboratories president Dean Y. Li framed the ambition specifically as resected stage IIB-IV disease ^[24].

Watch three things: the effect size when the full dataset is presented and taken to regulators ^[7], overall survival ^[13], and whether the squeeze-driven portion of the rally unwinds. Nagda also argued Moderna is now an acquisition target and still undervalued ^[22]; that view is his alone.